论文部分内容阅读
干细胞可分化为构成人体的250余种细胞,这一特性为彻底攻克人类疾病带来了极大的希望,然而,现阶段也存在大量亟待解决的问题。干细胞基础研究结果应用于临床试验还有许多问题没有解决,仍然需要包括动物实验等中间试验在内的数据积累。干细胞应用前期的临床试验面临的科研人员职业道德的挑战、科学实验立论不够严谨、急功近利的虚假研究报道等问题必须坚决杜绝,在此基础上才能加快干细胞再生生物学从基础及临床试验走向临床应用的步伐。中国干细胞临床应用相关的法律法规必须借鉴发达国家的经验,组建至少包括法律界资深学者、医学伦理学专家、再生生物学领域的一线科研工作者和政治政策的制定者在内的干细胞应用相关法律委员会,颁布符合国情的法律。
Stem cells can differentiate into more than 250 kinds of cells that make up the human body. This feature brings great hope for the complete solution of human diseases. However, there are still a lot of problems to be solved at this stage. There are many problems with basic research results of stem cells used in clinical trials that remain unresolved and still require data accumulation including intermediate tests such as animal experiments. Stem cells used in pre-clinical trials facing the challenges of scientific research personnel professional ethics, scientific experiments rigorous rigor, quick success and false research reports and other issues must be resolutely eradicated, on this basis to speed up stem cell regeneration biology from basic and clinical trials to clinical applications pace of. The laws and regulations related to the clinical application of stem cells in China must draw on the experience of developed countries and establish relevant laws on the application of stem cells, including at least senior legal scholars, medical ethics experts, first-line scientific researchers in field of regenerative biology and policy makers The Commission promulgated the law in line with the national conditions.